A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumors.
Authors: Amita Patnaik, William Bennion McKean, David M. O'Malley, Ravi Kumar Paluri, Shivani Gupta, Kevin Kim, Meredith Pelster